Dr. Petrylak: The Future of Prostate Cancer

Patients with PSMA-positive metastatic castration-resistant prostate cancer showed benefits after receiving PSMA-targeted treatment.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

An expert explains how attitudes towards lymphedema risk have evolved over the years.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Researchers have found an association between baseline circulating tumor cell count and survival in metastatic hormone-sensitive prostate cancer.

Ponsegromab helped patients with cachexia and elevated GDF-15 levels gain weight, increase activity and improve cachexia symptoms, with manageable safety.